INS and metabolic syndrome: Among them, eriodictyol can improve dyslipidemia, fatty liver and IR in diet-induced obese mice (Kwon and Choi, 2019), promote insulin release through the cAMP/PKA pathway, which is related to the activation of GLP-1R.